Author

N. Van

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Approach:experimental assay· 2 Approach:machine learning (classical)· 2 Organism:bacteria (other)· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

B. B. Aldridge· 4 shared J. Larkins-Ford· 3 shared Y. N. Degefu· 3 shared A. Sokolov· 2 shared F. P. Maurer· 2 shared A. Parret· 1 shared C. M. Thorpe· 1 shared D. Stone· 1 shared

Activity by Year

2021-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

B. B. Aldridge

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Novel synergies and isolate specificities in the drug interactions landscape of Mycobacterium abscessus

N. Van, Y. N. Degefu, P. A. Leus, J. Larkins-Ford, J. Klickstein, F. P. Maurer, D. Stone, H. Poonawala, C. M. Thorpe, T. C. Smith, B. B. Aldridge

This study systematically measures drug interactions in Mycobacterium abscessus to identify synergistic combinations and highlight strain-specific responses.

bioRxiv · Dec 12, 2022Microbiology

Design principles to assemble drug combinations for effective tuberculosis therapy using interpretable pairwise drug response measurements

J. Larkins-Ford, Y. N. Degefu, N. Van, A. Sokolov, B. B. Aldridge

The paper uses pairwise drug response data to train machine learning models predicting effective tuberculosis drug combinations, revealing design principles for rational combination therapy.

bioRxiv · Dec 5, 2021Microbiology

C25-modified rifamycin derivatives with improved activity against Mycobacterium abscessus

L. Paulowski, K. S. H. Beckham, M. D. Johansen, L. Berneking, N. Van, Y. Degefu, S. Staack, F. Vasquez Sotomayor, L. Asar, H. Rohde, B. B. Aldridge, M. Aepfelbacher, A. Parret, M. Wilmanns, L. Kremer, , F. P. Maurer

This study develops a C25-modified rifamycin derivative, 5j, which resists enzymatic inactivation by ArrMab and shows potent antimicrobial activity against M. abscessus in vitro and in macrophages.

bioRxiv · Jul 12, 2021Microbiology

Systematic measurement of combination drug landscapes to predict in vivo treatment outcomes for tuberculosis

J. Larkins-Ford, T. Greenstein, N. Van, Y. N. Degefu, M. C. Olson, A. Sokolov, B. B. Aldridge

The paper systematically measures drug combinations to predict tuberculosis treatment outcomes using in vitro models and machine learning.

bioRxiv · Feb 3, 2021Microbiology